Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Mineralys Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Bank of America Securities Health Care Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mineralys Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Bank of America Securities Health Care Conference. The company focuses on developing medicines for hypertension, chronic kidney disease, and diseases driven by dysregulated aldosterone. The event will take place in Las Vegas on May 14-16, 2024. Investors can access a live webcast and replay of the chat on the company's website.
Details
News Market Reaction – MLYS
The recorded move for MLYS in the trading session of this news was +6.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.
| Bank of America Securities Health Care Conference: | |
| Date: | Wednesday, May 15, 2024 |
| Time: | 5:00pm PDT |
| Format: | Fireside Chat |
A live webcast of the fireside chat can be accessed by clicking here or under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the fireside chat will be available on the Company’s website for approximately 90 days.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.